Buy Rating on Context Therapeutics's CTIM-76 Bolstered by Market Validation and Competitive Edge
TipRanksApr 11 13:15 ET
Express News | Context Therapeutics Submitted An FDA Investigational New Drug To Begin Phase 1 Dose Escalation And Expansion Trial Of CTIM-76 For Claudin 6-Positive Gynecologic And Testicular Cancers
Moomoo 24/7Apr 1 07:46 ET
Context Therapeutics Advances Cancer Trial With FDA Submission
TipRanksApr 1 07:42 ET
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
Important Regulatory Milestone Supports Next Phase of CTIM-76 DevelopmentPHILADELPHIA, April 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a bio
GlobeNewswireApr 1 07:30 ET
Buy Rating Justified by Advances in T Cell Engagers and Context Therapeutics' Strategic Drug Positioning
TipRanksMar 22 13:55 ET
Context Therapeutics Price Target Cut to $4.00/Share From $5.00 by HC Wainwright & Co.
Context Therapeutics Price Target Cut to $4.00/Share From $5.00 by HC Wainwright & Co.
Dow JonesMar 21 12:31 ET
Context Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Context Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow JonesMar 21 12:31 ET
Express News | HC Wainwright & Co. Maintains Buy on Context Therapeutics, Lowers Price Target to $4
Moomoo 24/7Mar 21 12:21 ET
Context Therapeutics Reports FY Results
Seeking AlphaMar 21 10:44 ET
Express News | Context Therapeutics Reported FY23 EPS Loss of $(1.50) Vs $(0.93) YoY, Cash Balance of $14.4M
Moomoo 24/7Mar 21 07:49 ET
Press Release: Context Therapeutics Reports Full Year 2023 Operating and Financial Results
Context Therapeutics Reports Full Year 2023 Operating and Financial Results CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Compan
Dow JonesMar 21 07:43 ET
Context Therapeutics Unveils Updated Corporate Strategy Presentation
TipRanksMar 6 07:42 ET
12 Health Care Stocks Moving In Friday's After-Market Session
GainersAclarion (NASDAQ:ACON) stock rose 21.6% to $3.82 during Friday's after-market session. The company's market cap stands at $3.2 million. Outset Medical (NASDAQ:OM) shares rose 10.61% to $4.95. T
BenzingaJan 12 16:31 ET
Constellation Energy, Battalion Oil And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mixed, with the Nasdaq Composite gaining around 60 points on Friday. Here are some other big stocks recording gains in today's session. Battalion Oil Corporation (NYSE:BATL) rose 8
BenzingaDec 15, 2023 10:21 ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersExicure (NASDAQ:XCUR) stock increased by 63.9% to $0.66 during Friday's pre-market session. The market value of their outstanding shares is at $5.7 million. Atreca (NASDAQ:BCEL) shares rose 17.
BenzingaDec 8, 2023 08:07 ET
Context Therapeutics' Promising Financial and Preclinical Results Bolster Buy Rating: A Focus on CTIM-76's High Potency and Target Specificity
TipRanksNov 11, 2023 07:06 ET
Promising Potential of CTIM-76 Drug: A Comprehensive Buy Rating Analysis for Context Therapeutics
TipRanksNov 10, 2023 06:47 ET
Context Therapeutics GAAP EPS of -$0.37 Misses by $0.06
Seeking AlphaNov 9, 2023 17:45 ET
Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results
CTIM-76 IND filing on track for late Q1 2024 Cash and cash equivalents of $21.7 million as of September 30, 2023 Company expects its cash and cash equivalents will continue to fund operations into lat
GlobeNewswireNov 9, 2023 16:15 ET
Context Therapeutics Price Target Announced at $5.00/Share by HC Wainwright & Co.
Context Therapeutics Price Target Announced at $5.00/Share by HC Wainwright & Co.
Dow JonesNov 1, 2023 07:27 ET
No Data
No Data